Tisdag 29 April | 09:45:58 Europe / Stockholm

Kalender

Est. tid*
2024-11-20 - Årsstämma
2024-10-31 - X-dag ordinarie utdelning CVSG 8.00 GBP
2024-09-26 - Kvartalsrapport 2024-Q2
2022-11-17 - X-dag ordinarie utdelning CVSG 7.00 GBP
2021-11-18 - X-dag ordinarie utdelning CVSG 6.50 GBP
2019-11-21 - X-dag ordinarie utdelning CVSG 5.50 GBP
2018-11-22 - X-dag ordinarie utdelning CVSG 5.00 GBP
2017-11-23 - X-dag ordinarie utdelning CVSG 4.50 GBP
2016-11-24 - X-dag ordinarie utdelning CVSG 3.50 GBP
2015-11-26 - X-dag ordinarie utdelning CVSG 3.33 GBP
2014-12-04 - X-dag ordinarie utdelning CVSG 2.78 GBP
2013-12-04 - X-dag ordinarie utdelning CVSG 2.22 GBP
2012-12-05 - X-dag ordinarie utdelning CVSG 1.67 GBP
2011-12-14 - X-dag ordinarie utdelning CVSG 1.11 GBP
2024-07-31 08:00:12

31 July 2024

CVS Group plc

("CVS" or the "Company")

Exercise of Options and Total Voting Rights

CVS, one of the UK's leading providers of integrated veterinary services, confirms that certain employees have exercised options during July under the CVS Group 2020 SAYE Plan (2020/2024) totalling 5,468 ordinary shares of 0.2 pence each ("Ordinary Shares").

The sum of 5,468 new Ordinary Shares were issued to satisfy the balance of Ordinary Shares arising from the SAYE Exercise.  Admission of the 5,468 new Ordinary Shares has been satisfied by the Company's block listing admitted to the London Stock Exchange on 30 December 2021. 

Following the issue of these new Ordinary Shares, which rank pari passu in all respects with the Company's existing Ordinary Shares, the Company has a total issued share capital of 71,737,601 Ordinary Shares, each carrying one voting right. The Company holds no Ordinary Shares in treasury and the total number of voting rights is therefore 71,737,601.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts:

CVS Group plc                                                                                                       via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker)                                                 +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark / Lalit Bose

   Berenberg (Joint Broker)                                                                                   +44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

Camarco (Financial PR)                                                                                             

Geoffrey Pelham-Lane                                                                                         +44 (0)7733 124 226

Ginny Pulbrook                                                                                                     +44 (0)7961 315 138

 



About CVS Group plc ( www.cvsukltd.co.uk )

CVS Group is an AIM-listed provider of veterinary services with operations in the UK, and Australia.  CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.460 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties), Crematoria (providing pet cremation and clinical waste disposal for CVS and third-party practices) and an online retail business ("Animed Direct").

The Group employs c.9,000 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.